



CS/NSE&BSE/UFR/2017-18  
August 14, 2017

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**To**  
**The General Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**

**Stock Code: SUVEN–EQ**

**Stock Code: 530239**

Dear Sir/Madam,

**Sub: Notification of Un-audited Financial Results for the quarter ended 30th June, 2017**

.....

With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 14th August, 2017, has taken on record the Standalone Un-audited Financial Results of the Company under Ind AS for the quarter ended 30th June, 2017.

We are enclosing herewith the **Un-audited Financial Results** under Ind AS for the quarter ended 30th June, 2017 along with **Limited Review Report of Statutory Auditors of the Company**.

We hereby notify that in terms of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 our Company will submit standalone financial results for the financial year 2017-2018.

Please find enclosed **Press Release** of our company. We request you to take these documents on your records.

Thanking you,  
Yours faithfully,  
For **Suven Life Sciences Limited**

A handwritten signature in black ink, appearing to read 'K Hanumantha Rao'.

**K Hanumantha Rao**  
Company Secretary

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7  
Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com



## SUVEN LIFE SCIENCES LIMITED


Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvен.com website: www.suven.com

## STATEMENT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2017

All amounts in Indian Rupees in lakhs

Sl. No.	Particulars	For the Quarter Ended			For the Year Ended
		30-Jun-2017	31-Mar-2017	30-Jun-2016	31-Mar-2017
		Un-audited	Audited	Un-audited	Audited
<b>1</b>	<b>Revenue from operations</b>				
	(a) Net sales/income from operations (inclusive of excise duty)	13,744.90	17,499.64	13,322.70	53,916.74
	(b) Other operating income	357.00	515.15	-	531.04
	<b>Total Revenue from operations</b>	<b>14,101.90</b>	<b>18,014.79</b>	<b>13,322.70</b>	<b>54,447.78</b>
<b>2</b>	<b>Other Income</b>	562.29	493.85	449.70	2,109.25
	<b>Total Income (1+2)</b>	<b>14,664.19</b>	<b>18,508.64</b>	<b>13,772.40</b>	<b>56,557.03</b>
<b>3</b>	<b>Expenses</b>				
	(a) Cost of materials consumed	3,683.53	4,235.36	3,985.98	15,480.66
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(227.17)	2,234.61	(36.77)	(295.94)
	(d) Employee benefits expense	1,566.22	1,453.53	1,146.96	5,064.46
	(e) Finance costs	127.01	156.82	159.56	566.58
	(f) Depreciation and amortisation expenses	519.20	718.31	480.58	2,141.31
	(g) Manufacturing expenses	2,190.37	2,531.43	1,741.04	8,157.37
	(h) Research & Development expenses	1,601.19	1,923.75	1,469.01	6,494.09
	(i) Other expenses	759.06	819.49	673.07	3,012.81
	<b>Total expenses</b>	<b>10,219.41</b>	<b>14,073.30</b>	<b>9,619.43</b>	<b>40,621.34</b>
<b>4</b>	<b>Profit before exceptional items and tax (1+2-3)</b>	<b>4,444.78</b>	<b>4,435.34</b>	<b>4,152.97</b>	<b>15,935.69</b>
<b>5</b>	<b>Exceptional Items</b>	-	-	-	-
<b>6</b>	<b>Profit before tax (4 - 5)</b>	<b>4,444.78</b>	<b>4,435.34</b>	<b>4,152.97</b>	<b>15,935.69</b>
<b>7</b>	<b>Tax Expenses</b>				
	(a) Current tax	1,132.77	143.47	886.31	3,275.07
	(b) Deferred tax	354.94	284.90	9.05	313.25
<b>8</b>	<b>Net Profit for the period / year (6-7)</b>	<b>2,957.07</b>	<b>4,006.97</b>	<b>3,257.61</b>	<b>12,347.37</b>
<b>9</b>	<b>Other Comprehensive Income</b>				
<b>9.A</b>	(i) Items that will not be reclassified to profit or loss	(3.73)	36.96	(11.30)	(14.90)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	1.29	(12.79)	-	5.15
<b>9.B</b>	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	<b>Total Other Comprehensive Income</b>	<b>(2.44)</b>	<b>24.17</b>	<b>(11.30)</b>	<b>(9.75)</b>
	<b>Total Comprehensive Income (8+9)</b>	<b>2,954.63</b>	<b>4,031.14</b>	<b>3,246.31</b>	<b>12,337.62</b>
<b>10</b>	<b>Paid-up equity share capital (face value of Rs. 1/- each)</b>	<b>1,272.82</b>	<b>1,272.82</b>	<b>1,272.82</b>	<b>1,272.82</b>
<b>11</b>	<b>Earning Per Share (EPS) for continuing operation (face value of Rs.1/- each):</b>				
	a) Basic	2.32	3.17	2.55	9.69
	b) Diluted	2.32	3.17	2.55	9.69

See accompanying notes to the financial statements




**SEGMENT WISE REVENUE, RESULTS TOTAL ASSETS AND LIABILITIES**

PARTICULARS	For the Quarter Ended			For the Year Ended
	30-Jun-2017	31-Mar-2017	30-Jun-2016	31-Mar-2017
	Un-audited	Audited	Un-audited	Audited
<b>1 SEGMENT REVENUE</b>				
a) Manufacturing (CRAMS)	13,330.76	17,500.16	12,766.39	51,670.07
b) Services (DDDSS)	771.14	514.63	556.31	2,777.71
c) Research & Development	-	-	-	-
<b>Total</b>	<b>14,101.90</b>	<b>18,014.79</b>	<b>13,322.70</b>	<b>54,447.78</b>
Less: Inter Segment Revenue	-	-	-	-
<b>Net Sales/Income from Operations</b>	<b>14,101.90</b>	<b>18,014.79</b>	<b>13,322.70</b>	<b>54,447.78</b>
<b>2 SEGMENT RESULTS (Profit/(Loss) before tax and interest)</b>				
a) Manufacturing (CRAMS)	5,782.86	6,342.38	5,596.76	21,634.85
b) Services (DDDSS)	405.25	275.68	258.68	1,476.81
c) Research & Development	(1,601.18)	(1,923.75)	(1,469.01)	(6,494.09)
<b>TOTAL</b>	<b>4,586.93</b>	<b>4,694.31</b>	<b>4,386.43</b>	<b>16,617.57</b>
Less: i) Finance Cost	87.11	75.01	113.26	376.38
ii) Other Un-allocable expenditure /(income), net	55.04	183.96	120.20	305.50
<b>Total Profit Before Tax</b>	<b>4,444.78</b>	<b>4,435.34</b>	<b>4,152.97</b>	<b>15,935.69</b>
<b>3 SEGMENT ASSETS :</b>				
a) Manufacturing (CRAMS)	47,190.09	43,886.93	43,126.18	43,886.93
b) Services (DDDSS)	3,511.49	2,828.60	3,700.16	2,828.60
c) Research & Development	2,540.08	2,609.60	2,423.33	2,609.60
d) Un allocated	37,517.52	38,291.82	30,681.23	38,291.82
<b>TOTAL</b>	<b>90,759.18</b>	<b>87,616.95</b>	<b>79,930.90</b>	<b>87,616.95</b>
<b>4 SEGMENT LIABILITIES :</b>				
a) Manufacturing (CRAMS)	8,830.42	8,547.86	7,764.83	8,547.86
b) Services (DDDSS)	428.06	370.23	322.33	370.23
c) Research & Development	1,873.25	1,848.18	1,590.97	1,848.18
d) Un allocated	722.22	687.23	617.21	687.23
<b>TOTAL</b>	<b>11,853.95</b>	<b>11,453.50</b>	<b>10,295.34</b>	<b>11,453.50</b>

- Notes:**
- The Company has adopted Indian Accounting Standards ("Ind AS") from April 1 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial Results for all the period presented been prepared in accordance with the recognition and measurement principles of Ind AS 34.
  - The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 14th August 2017 and the same reviewed by the Statutory Auditors.
  - The corresponding previous period figures have been regrouped / reclassified where ever necessary.

For SUVEN LIFE SCIENCES LTD



*Venkata Jasti*

**VENKAT JASTI**  
Chairman & CEO  
DIN: 00278028

Place: Hyderabad  
Date: 14th August, 2017

*We Deliver*



**LIMITED REVIEW REPORT**

To

The Board of Directors of  
**SUVEN LIFE SCIENCES LIMITED**

1. We have reviewed the accompanying statement of unaudited financial results of **SUVEN LIFE SCIENCES LIMITED**, having registered office at SDE Serene Chambers, 6<sup>th</sup> Floor, Avenue 7, Road No. 5, Banjara Hills, Hyderabad – 500 034 , Telangana, for the quarter ended on 30.06.2017. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards prescribed under Section 133 of Companies Act 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. The review of the unaudited Standalone financial results for the quarter ended 30<sup>th</sup> June, 2016 and audited standalone financials results for the year ended 31<sup>st</sup> March, 2017 (including audited standalone financial results for the quarter ended 31<sup>st</sup> March, 2017) included in the Statement, was carried out and reported by M/s. KARVY & CO., vide their unmodified review and audit report dated 10<sup>th</sup> August, 2016 and 13<sup>th</sup> May, 2017 respectively, whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our review report is not qualified in respect of this matter.

M/s. **TUKARAM & CO.,**  
Chartered Accountants  
Firm registration No.0044365



**MURALI PACHARI**  
Partner  
M.No.221625



Place: Hyderabad  
Date: 14/08/2017

## News Release

### **Suven's Income at Rs. 1466 Mn; PAT at Rs. 295 Mn for the quarter ended June 2017**

**HYDERABAD, INDIA (14th August 2017)** – Suven Life Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders and Contract Research and Manufacturing Services (CRAMS) today announced its un-audited financial results for the quarter ending 30<sup>th</sup> June 2017. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14<sup>th</sup> August 2017 at Hyderabad.

Financial Highlights for the 1<sup>st</sup> Quarter ended June' 2017: (QoQ)

<b>Growth in revenue</b>	<b>INR 1466 Mn vs. INR 1851 Mn - Down by 20.77%</b>
<b>Growth in PAT</b>	<b>INR 295 Mn vs. INR 403 Mn - Down by 26.70%</b>
<b>Growth in EBIDTA</b>	<b>INR 509 Mn vs. INR 533 Mn - Down by 4.61%</b>

In comparison with the same period of last year, the income was higher by 6.48% and PAT was lower by 8.98%.

Suven's thrust on innovative R&D in Drug Discovery continues with a spending of Rs 160 Mn (10.92% on revenue) for the quarter ended 30<sup>th</sup> June 2017.

For more information on Suven please visit our Web site at <http://www.suven.com>

***Risk Statement:***

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained, if any, in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;*

## Suven Life Sciences Limited